Cite
HARVARD Citation
Roser‐Page, S. et al. (2018). CTLA‐4Ig (abatacept) balances bone anabolic effects of T cells and Wnt‐10b with antianabolic effects of osteoblastic sclerostin. Annals of the New York Academy of Sciences. 1415 (1), pp. 21-33. [Online].